Acer Therapeutics is part of the healthcare sector and is in the biotechnology industry. The company CEO is Chris Schelling. Acer Therapeutics Inc is a pharmaceutical company that acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need.
Previous Intraday Performance:
The ACER shares had a previous change of -1.86% which opened at 19.30 and closed at 18.75. It moved to an intraday high of 19.30 and a low of 18.20.
Historical Performance:
Over the last five trading days, ACER shares returned -3.30% and in the past 30 trading days it returned -30.19%. Over three months, it changed -21.15%. In one year it has changed -1.21% and within that year its 52 week high was 34.10 and its 52 week low was 16.02. ACER stock is 17.04% above its 52 week low.
Our calculations result in a 200 day moving average of 24.28 and a 50 day moving average of 21.91. Right now, ACER stock is trading -22.76% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
Liquidity:
The company has a market cap of $189.1m with 10.1m shares outstanding and a float of 10.1m shares. Trading volume was 101,072 shares and has experienced an average volume of 69,261 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Acer Therapeutics was -2.5 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.79.
Below was the last reported diluted earnings per share:
| 20 | 0.00 |
|---|---|
| 20 | 0.00 |
| 20 | 0.00 |
| 20 | 0.00 |
| 20 | 0.00 |
Base on our calculations, the intrinsic value per share is 105.97, which means it might be undervalued and has a margin of safety of 82.31%.
The long-term trend of the EPS is a vital number as it helps understand the future potential of Acer Therapeutics.
Indicators Also to Watch:
Based on the latest filings, there is 35.60% of institutional ownership.
The beta was calculated to be 2.39.
Business Wire: National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -92.38%, return on assets is -83.96% and price-to-book is 5.01.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: ACER, Acer Therapeutics, Biotechnology, Healthcare
